60 Degrees Pharmaceuticals, Inc. - Warrant (OQ:SXTPW)
Business Focus: N/A
May 02, 2024 07:59 am ET
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided comments on...
Apr 03, 2024 07:58 am ET
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor a pilot study of tafenoquine, the active...
Mar 14, 2024 07:59 am ET
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP, SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the U.S. Food and Drug...
Feb 20, 2024 07:59 am ET
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP; SXTPW), specialists in developing and marketing medicines for infectious diseases, today announced it will, through its majority-owned subsidiary...
Feb 08, 2024 07:59 am ET
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of...
Jan 31, 2024 11:15 am ET
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of...
Jan 30, 2024 09:00 am ET
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the pricing of...
Jan 22, 2024 07:59 am ET
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that, following a Type C meeting held on January 17, 2024 with...
Jan 16, 2024 07:59 am ET
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received written notice from the...
Dec 26, 2023 07:59 am ET
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today the approval of an Investigational Review Board (IRB) sanctioned...
Nov 15, 2023 07:29 am ET
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted a...
Oct 19, 2023 08:31 am ET
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, will present a poster titled, “Long-term safety of the tafenoquine antimalarial...
Oct 12, 2023 04:16 pm ET
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60P Australia Pty Ltd, will not re-submit its...
Sep 18, 2023 04:16 pm ET
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that 60P Australia Pty Ltd, a majority-owned subsidiary of 60P, has withdrawn its investigational...
Sep 06, 2023 07:31 am ET
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that CEO Dr. Geoff Dow and CFO Ty Miller will participate in the H.C....
Aug 30, 2023 07:32 am ET
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced the journal, New Microbes and New Infections, has published non-clinical study results showing...
Aug 22, 2023 07:31 am ET
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
60 Degrees Pharmaceuticals (“60P”) (Nasdaq: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that the United States Patent and Trademark Office (USPTO) has awarded 60P a patent covering the use of...
Aug 15, 2023 07:31 am ET
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
60 Degrees Pharmaceuticals, Inc. (“60 Degrees Pharmaceuticals” or “60P”) (NASDAQ: SXTP), a company specializing in developing and marketing medicines for infectious diseases, today announced that ACLR8-LR, a double-blind, randomized,...
Jul 31, 2023 07:59 am ET
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued the...
Jul 14, 2023 12:39 pm ET
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering
60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious diseases, announced today the closing of its initial public offering of 1,415,095 units (each, a...
Jul 12, 2023 12:29 pm ET
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its initial public offering of 1,415,095 units (each, a...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.